Kiniksa Pharmaceuticals (NASDAQ:KNSA) Stock Price Down 3.6%

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report)'s stock price was down 3.6% during mid-day trading on Wednesday . The company traded as low as $17.84 and last traded at $18.05. Approximately 75,230 shares were traded during trading, a decline of 82% from the average daily volume of 406,653 shares. The stock had previously closed at $18.73.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Wedbush reissued an "outperform" rating and issued a $30.00 target price (up previously from $28.00) on shares of Kiniksa Pharmaceuticals in a research note on Tuesday. TheStreet upgraded Kiniksa Pharmaceuticals from a "d+" rating to a "c" rating in a research report on Thursday, February 29th.

Kiniksa Pharmaceuticals Stock Performance

The firm has a market cap of $1.29 billion, a PE ratio of 101.33 and a beta of 0.27. The company's 50-day simple moving average is $19.71 and its two-hundred day simple moving average is $17.93.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last posted its earnings results on Wednesday, February 28th. The company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.15. Kiniksa Pharmaceuticals had a negative return on equity of 6.12% and a net margin of 5.11%. The company had revenue of $83.40 million for the quarter, compared to analysts' expectations of $72.31 million. On average, analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.05 EPS for the current year.

Insider Transactions at Kiniksa Pharmaceuticals

In related news, CAO Michael R. Megna sold 5,126 shares of the firm's stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $21.79, for a total value of $111,695.54. Following the completion of the sale, the chief accounting officer now owns 17,588 shares of the company's stock, valued at $383,242.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CAO Michael R. Megna sold 5,126 shares of the business's stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $21.79, for a total transaction of $111,695.54. Following the transaction, the chief accounting officer now owns 17,588 shares in the company, valued at $383,242.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Sanj K. Patel sold 12,742 shares of the stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $21.49, for a total transaction of $273,825.58. Following the completion of the transaction, the chief executive officer now directly owns 70,594 shares of the company's stock, valued at $1,517,065.06. The disclosure for this sale can be found here. In the last three months, insiders have sold 33,109 shares of company stock worth $709,929. 54.23% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Swiss National Bank lifted its position in Kiniksa Pharmaceuticals by 13.8% during the 1st quarter. Swiss National Bank now owns 60,100 shares of the company's stock valued at $597,000 after acquiring an additional 7,300 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Kiniksa Pharmaceuticals by 23.8% during the first quarter. JPMorgan Chase & Co. now owns 17,825 shares of the company's stock valued at $177,000 after purchasing an additional 3,431 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Kiniksa Pharmaceuticals by 2.3% during the first quarter. Bank of New York Mellon Corp now owns 137,001 shares of the company's stock valued at $1,363,000 after purchasing an additional 3,095 shares during the last quarter. BlackRock Inc. boosted its position in shares of Kiniksa Pharmaceuticals by 0.3% in the 1st quarter. BlackRock Inc. now owns 3,494,325 shares of the company's stock worth $34,734,000 after purchasing an additional 10,473 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of Kiniksa Pharmaceuticals by 126.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 360,940 shares of the company's stock worth $3,588,000 after buying an additional 201,622 shares during the last quarter. 53.95% of the stock is currently owned by institutional investors.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.